Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Long-Term Capital Lease Obligation : ¥15 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Long-Term Capital Lease Obligation?

Shijiazhuang Yiling Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥15 Mil.

Shijiazhuang Yiling Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (¥13 Mil) to Dec. 2023 (¥13 Mil) and increased from Dec. 2023 (¥13 Mil) to Mar. 2024 (¥15 Mil).

Shijiazhuang Yiling Pharmaceutical Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (¥13 Mil) to Dec. 2022 (¥15 Mil) but then declined from Dec. 2022 (¥15 Mil) to Dec. 2023 (¥13 Mil).

Shijiazhuang Yiling Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

10.54

12.53

14.97

13.01

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															14.04	13.27	12.66	13.01	14.83

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Shijiazhuang Yiling Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN

Website

http://www.yiling.cn/

Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.

Executives

Zhang Qiu Lian	Directors, executives
Han Yue Zhi	Executives
Zhao Shao Hua	Executives
Wang Wei	Executives
Gao Xue Dong	Supervisors
Wu Yi Ling	Director
Gao Xiu Qiang	Executives
Wu Xiang Jun	Directors, executives
Guo Shuang Geng	Director
Wang Hua	Securities Affairs Representative
Dai Feng Xiang	Directors, executives
Liu Gen Wu	Supervisors
Wang Wei Ping	Directors, executives
Xu Wei Dong	Director
Wu Rui	Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines